APO Research
Talk to an analyst

APO RESEARCH · REPORT

Virus Like Particles

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Virus Like Particles Market Outlook and Growth Opportunities 2026

30 December 2025199 pages

Choose your research edition.

Industry ResearchVirus Like Particles Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Virus Like Particles Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Virus Like Particles Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Virus Like Particles Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Virus Like Particles Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Virus Like Particles market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Virus Like Particles is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Virus Like Particles market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Virus Like Particles market include Agilvax, Allergy Therapeutics, ANGANY Genetics, CPL Biologicals, Cytos Biotechnology, GeoVax Labs, Medicago, MedImmune and Novavax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Virus Like Particles market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Virus Like Particles and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Virus Like Particles sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Virus Like Particles market size, projected growth trends, production technologies, key applications, and end-use industries.

Virus Like Particles Segment by Company

Agilvax

Allergy Therapeutics

ANGANY Genetics

CPL Biologicals

Cytos Biotechnology

GeoVax Labs

Medicago

MedImmune

Novavax

Serum Institute of India

TechnoVax

Xiamen Innovax Biotech

GlaxoSmithKline

Merck

Takeda

Virus Like Particles Segment by Type

Hepatitis B Virus

Adeno-Associated Virus

Hepatitis C Virus

HIV

Others

Virus Like Particles Segment by Application

Therapeutic and Imaging Agents

Mycoviruses

Vaccines

Virus Research

Others

Virus Like Particles Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Virus Like Particles status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Virus Like Particles market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Virus Like Particles significant trends, drivers, influence factors in global and regions.

6. To analyze Virus Like Particles competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus Like Particles market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Virus Like Particles and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus Like Particles.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Virus Like Particles market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Virus Like Particles industry.

Chapter 3: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Virus Like Particles in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Virus Like Particles in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Virus Like Particles Industry Trends Table 2. Virus Like Particles Industry Drivers Table 3. Virus Like Particles Industry Opportunities and Challenges Table 4. Virus Like Particles Industry Restraints Table 5. Global Virus Like Particles Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Virus Like Particles Revenue Share by Company (2021-2026) Table 7. Global Virus Like Particles Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Virus Like Particles Sales Volume Share by Company (2021-2026) Table 9. Global Virus Like Particles Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Virus Like Particles Company Ranking, (2024-2026) & (USD Million) Table 11. Global Virus Like Particles Key Company Manufacturing Base & Headquarters Table 12. Global Virus Like Particles Company, Product Type & Application Table 13. Global Virus Like Particles Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Virus Like Particles by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hepatitis B Virus Table 18. Significant Companies of Adeno-Associated Virus Table 19. Significant Companies of Hepatitis C Virus Table 20. Significant Companies of HIV Table 21. Significant Companies of Others Table 22. Global Virus Like Particles Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Virus Like Particles Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Virus Like Particles Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Virus Like Particles Sales Volume Share by Type (2021-2026) Table 26. Global Virus Like Particles Sales Volume Share by Type (2027-2032) Table 27. Global Virus Like Particles Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Virus Like Particles Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Virus Like Particles Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Virus Like Particles Sales Value Share by Type (2021-2026) Table 31. Global Virus Like Particles Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Therapeutic and Imaging Agents Table 33. Significant Companies of Mycoviruses Table 34. Significant Companies of Vaccines Table 35. Significant Companies of Virus Research Table 36. Significant Companies of Others Table 37. Global Virus Like Particles Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Virus Like Particles Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Virus Like Particles Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Virus Like Particles Sales Volume Share by Application (2021-2026) Table 41. Global Virus Like Particles Sales Volume Share by Application (2027-2032) Table 42. Global Virus Like Particles Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Virus Like Particles Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Virus Like Particles Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Virus Like Particles Sales Value Share by Application (2021-2026) Table 46. Global Virus Like Particles Sales Value Share by Application (2027-2032) Table 47. Global Virus Like Particles Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Virus Like Particles Sales by Region (2021-2026) & (K Units) Table 49. Global Virus Like Particles Sales Market Share by Region (2021-2026) Table 50. Global Virus Like Particles Sales by Region (2027-2032) & (K Units) Table 51. Global Virus Like Particles Sales Market Share by Region (2027-2032) Table 52. Global Virus Like Particles Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Virus Like Particles Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Virus Like Particles Sales Value Share by Region (2021-2026) Table 55. Global Virus Like Particles Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Virus Like Particles Sales Value Share by Region (2027-2032) Table 57. Global Virus Like Particles Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Virus Like Particles Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Virus Like Particles Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Virus Like Particles Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Virus Like Particles Sales by Country (2021-2026) & (K Units) Table 62. Global Virus Like Particles Sales Market Share by Country (2021-2026) Table 63. Global Virus Like Particles Sales by Country (2027-2032) & (K Units) Table 64. Global Virus Like Particles Sales Market Share by Country (2027-2032) Table 65. Global Virus Like Particles Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Virus Like Particles Sales Value Market Share by Country (2021-2026) Table 67. Global Virus Like Particles Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Virus Like Particles Sales Value Market Share by Country (2027-2032) Table 69. Agilvax Company Information Table 70. Agilvax Business Overview Table 71. Agilvax Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Agilvax Virus Like Particles Product Portfolio Table 73. Agilvax Recent Development Table 74. Allergy Therapeutics Company Information Table 75. Allergy Therapeutics Business Overview Table 76. Allergy Therapeutics Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Allergy Therapeutics Virus Like Particles Product Portfolio Table 78. Allergy Therapeutics Recent Development Table 79. ANGANY Genetics Company Information Table 80. ANGANY Genetics Business Overview Table 81. ANGANY Genetics Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. ANGANY Genetics Virus Like Particles Product Portfolio Table 83. ANGANY Genetics Recent Development Table 84. CPL Biologicals Company Information Table 85. CPL Biologicals Business Overview Table 86. CPL Biologicals Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. CPL Biologicals Virus Like Particles Product Portfolio Table 88. CPL Biologicals Recent Development Table 89. Cytos Biotechnology Company Information Table 90. Cytos Biotechnology Business Overview Table 91. Cytos Biotechnology Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Cytos Biotechnology Virus Like Particles Product Portfolio Table 93. Cytos Biotechnology Recent Development Table 94. GeoVax Labs Company Information Table 95. GeoVax Labs Business Overview Table 96. GeoVax Labs Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. GeoVax Labs Virus Like Particles Product Portfolio Table 98. GeoVax Labs Recent Development Table 99. Medicago Company Information Table 100. Medicago Business Overview Table 101. Medicago Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Medicago Virus Like Particles Product Portfolio Table 103. Medicago Recent Development Table 104. MedImmune Company Information Table 105. MedImmune Business Overview Table 106. MedImmune Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. MedImmune Virus Like Particles Product Portfolio Table 108. MedImmune Recent Development Table 109. Novavax Company Information Table 110. Novavax Business Overview Table 111. Novavax Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Novavax Virus Like Particles Product Portfolio Table 113. Novavax Recent Development Table 114. Serum Institute of India Company Information Table 115. Serum Institute of India Business Overview Table 116. Serum Institute of India Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Serum Institute of India Virus Like Particles Product Portfolio Table 118. Serum Institute of India Recent Development Table 119. TechnoVax Company Information Table 120. TechnoVax Business Overview Table 121. TechnoVax Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. TechnoVax Virus Like Particles Product Portfolio Table 123. TechnoVax Recent Development Table 124. Xiamen Innovax Biotech Company Information Table 125. Xiamen Innovax Biotech Business Overview Table 126. Xiamen Innovax Biotech Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Xiamen Innovax Biotech Virus Like Particles Product Portfolio Table 128. Xiamen Innovax Biotech Recent Development Table 129. GlaxoSmithKline Company Information Table 130. GlaxoSmithKline Business Overview Table 131. GlaxoSmithKline Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. GlaxoSmithKline Virus Like Particles Product Portfolio Table 133. GlaxoSmithKline Recent Development Table 134. Merck Company Information Table 135. Merck Business Overview Table 136. Merck Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Merck Virus Like Particles Product Portfolio Table 138. Merck Recent Development Table 139. Takeda Company Information Table 140. Takeda Business Overview Table 141. Takeda Virus Like Particles Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Takeda Virus Like Particles Product Portfolio Table 143. Takeda Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Virus Like Particles Distributors List Table 147. Virus Like Particles Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Virus Like Particles Product Image Figure 2. Global Virus Like Particles Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Virus Like Particles Sales Value (2021-2032) & (US$ Million) Figure 4. Global Virus Like Particles Sales (2021-2032) & (K Units) Figure 5. Global Virus Like Particles Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Virus Like Particles Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hepatitis B Virus Image Figure 10. Adeno-Associated Virus Image Figure 11. Hepatitis C Virus Image Figure 12. HIV Image Figure 13. Others Image Figure 14. Global Virus Like Particles Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Virus Like Particles Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Virus Like Particles Sales Volume Share by Type (2021-2032) Figure 17. Global Virus Like Particles Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Virus Like Particles Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Virus Like Particles Sales Value Share by Type (2021-2032) Figure 20. Therapeutic and Imaging Agents Image Figure 21. Mycoviruses Image Figure 22. Vaccines Image Figure 23. Virus Research Image Figure 24. Others Image Figure 25. Global Virus Like Particles Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Virus Like Particles Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Virus Like Particles Sales Volume Share by Application (2021-2032) Figure 28. Global Virus Like Particles Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Virus Like Particles Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Virus Like Particles Sales Value Share by Application (2021-2032) Figure 31. Global Virus Like Particles Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Virus Like Particles Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Virus Like Particles Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Virus Like Particles Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Virus Like Particles Sales Value (2021-2032) & (US$ Million) Figure 36. North America Virus Like Particles Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Virus Like Particles Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Virus Like Particles Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Virus Like Particles Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Virus Like Particles Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Virus Like Particles Sales Value (2021-2032) & (US$ Million) Figure 42. South America Virus Like Particles Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Virus Like Particles Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Virus Like Particles Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Virus Like Particles Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Virus Like Particles Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Virus Like Particles Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Virus Like Particles Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Virus Like Particles Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis B Virus
  • Adeno-Associated Virus
  • Hepatitis C Virus
  • HIV
  • Others
Applications
  • Therapeutic and Imaging Agents
  • Mycoviruses
  • Vaccines
  • Virus Research
  • Others
Companies covered
  • Agilvax
  • Allergy Therapeutics
  • ANGANY Genetics
  • CPL Biologicals
  • Cytos Biotechnology
  • GeoVax Labs
  • Medicago
  • MedImmune
  • Novavax
  • Serum Institute of India
  • TechnoVax
  • Xiamen Innovax Biotech
  • GlaxoSmithKline
  • Merck
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Virus Like Particles Sales Value (2021-2032)
  4. 1.2.2 Global Virus Like Particles Sales Volume (2021-2032)
  5. 1.2.3 Global Virus Like Particles Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Virus Like Particles Market Dynamics
  1. 2.1 Virus Like Particles Industry Trends
  2. 2.2 Virus Like Particles Industry Drivers
  3. 2.3 Virus Like Particles Industry Opportunities and Challenges
  4. 2.4 Virus Like Particles Industry Restraints
3 Virus Like Particles Market by Company
  1. 3.1 Global Virus Like Particles Company Revenue Ranking in 2025
  2. 3.2 Global Virus Like Particles Revenue by Company (2021-2026)
  3. 3.3 Global Virus Like Particles Sales Volume by Company (2021-2026)
  4. 3.4 Global Virus Like Particles Average Price by Company (2021-2026)
  5. 3.5 Global Virus Like Particles Company Ranking (2024-2026)
  6. 3.6 Global Virus Like Particles Company Manufacturing Base and Headquarters
  7. 3.7 Global Virus Like Particles Company Product Type and Application
  8. 3.8 Global Virus Like Particles Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Virus Like Particles Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Virus Like Particles Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Virus Like Particles Market by Type
  1. 4.1 Virus Like Particles Type Introduction
  2. 4.1.1 Hepatitis B Virus
  3. 4.1.2 Adeno-Associated Virus
  4. 4.1.3 Hepatitis C Virus
  5. 4.1.4 HIV
  6. 4.1.5 Others
  7. 4.2 Global Virus Like Particles Sales Volume by Type
  8. 4.2.1 Global Virus Like Particles Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Virus Like Particles Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Virus Like Particles Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Virus Like Particles Sales Value by Type
  12. 4.3.1 Global Virus Like Particles Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Virus Like Particles Sales Value by Type (2021-2032)
  14. 4.3.3 Global Virus Like Particles Sales Value Share by Type (2021-2032)
5 Virus Like Particles Market by Application
  1. 5.1 Virus Like Particles Application Introduction
  2. 5.1.1 Therapeutic and Imaging Agents
  3. 5.1.2 Mycoviruses
  4. 5.1.3 Vaccines
  5. 5.1.4 Virus Research
  6. 5.1.5 Others
  7. 5.2 Global Virus Like Particles Sales Volume by Application
  8. 5.2.1 Global Virus Like Particles Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Virus Like Particles Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Virus Like Particles Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Virus Like Particles Sales Value by Application
  12. 5.3.1 Global Virus Like Particles Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Virus Like Particles Sales Value by Application (2021-2032)
  14. 5.3.3 Global Virus Like Particles Sales Value Share by Application (2021-2032)
6 Virus Like Particles Regional Sales and Value Analysis
  1. 6.1 Global Virus Like Particles Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Virus Like Particles Sales by Region (2021-2032)
  3. 6.2.1 Global Virus Like Particles Sales by Region: 2021-2026
  4. 6.2.2 Global Virus Like Particles Sales by Region (2027-2032)
  5. 6.3 Global Virus Like Particles Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Virus Like Particles Sales Value by Region (2021-2032)
  7. 6.4.1 Global Virus Like Particles Sales Value by Region: 2021-2026
  8. 6.4.2 Global Virus Like Particles Sales Value by Region (2027-2032)
  9. 6.5 Global Virus Like Particles Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Virus Like Particles Sales Value (2021-2032)
  12. 6.6.2 North America Virus Like Particles Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Virus Like Particles Sales Value (2021-2032)
  15. 6.7.2 Europe Virus Like Particles Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Virus Like Particles Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Virus Like Particles Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Virus Like Particles Sales Value (2021-2032)
  21. 6.9.2 South America Virus Like Particles Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Virus Like Particles Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Virus Like Particles Sales Value Share by Country, 2025 VS 2032
7 Virus Like Particles Country-level Sales and Value Analysis
  1. 7.1 Global Virus Like Particles Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Virus Like Particles Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Virus Like Particles Sales by Country (2021-2032)
  4. 7.3.1 Global Virus Like Particles Sales by Country (2021-2026)
  5. 7.3.2 Global Virus Like Particles Sales by Country (2027-2032)
  6. 7.4 Global Virus Like Particles Sales Value by Country (2021-2032)
  7. 7.4.1 Global Virus Like Particles Sales Value by Country (2021-2026)
  8. 7.4.2 Global Virus Like Particles Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Virus Like Particles Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Virus Like Particles Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Virus Like Particles Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Virus Like Particles Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Virus Like Particles Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Virus Like Particles Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Virus Like Particles Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Virus Like Particles Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Virus Like Particles Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Virus Like Particles Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Virus Like Particles Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Virus Like Particles Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Virus Like Particles Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Virus Like Particles Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Virus Like Particles Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Virus Like Particles Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Virus Like Particles Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Virus Like Particles Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Virus Like Particles Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Virus Like Particles Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Virus Like Particles Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Virus Like Particles Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Virus Like Particles Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Virus Like Particles Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Virus Like Particles Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Virus Like Particles Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Virus Like Particles Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Virus Like Particles Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Virus Like Particles Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Virus Like Particles Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Virus Like Particles Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilvax
  2. 8.1.1 Agilvax Company Information
  3. 8.1.2 Agilvax Business Overview
  4. 8.1.3 Agilvax Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Agilvax Virus Like Particles Product Portfolio
  6. 8.1.5 Agilvax Recent Developments
  7. 8.2 Allergy Therapeutics
  8. 8.2.1 Allergy Therapeutics Company Information
  9. 8.2.2 Allergy Therapeutics Business Overview
  10. 8.2.3 Allergy Therapeutics Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Allergy Therapeutics Virus Like Particles Product Portfolio
  12. 8.2.5 Allergy Therapeutics Recent Developments
  13. 8.3 ANGANY Genetics
  14. 8.3.1 ANGANY Genetics Company Information
  15. 8.3.2 ANGANY Genetics Business Overview
  16. 8.3.3 ANGANY Genetics Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 ANGANY Genetics Virus Like Particles Product Portfolio
  18. 8.3.5 ANGANY Genetics Recent Developments
  19. 8.4 CPL Biologicals
  20. 8.4.1 CPL Biologicals Company Information
  21. 8.4.2 CPL Biologicals Business Overview
  22. 8.4.3 CPL Biologicals Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CPL Biologicals Virus Like Particles Product Portfolio
  24. 8.4.5 CPL Biologicals Recent Developments
  25. 8.5 Cytos Biotechnology
  26. 8.5.1 Cytos Biotechnology Company Information
  27. 8.5.2 Cytos Biotechnology Business Overview
  28. 8.5.3 Cytos Biotechnology Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Cytos Biotechnology Virus Like Particles Product Portfolio
  30. 8.5.5 Cytos Biotechnology Recent Developments
  31. 8.6 GeoVax Labs
  32. 8.6.1 GeoVax Labs Company Information
  33. 8.6.2 GeoVax Labs Business Overview
  34. 8.6.3 GeoVax Labs Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GeoVax Labs Virus Like Particles Product Portfolio
  36. 8.6.5 GeoVax Labs Recent Developments
  37. 8.7 Medicago
  38. 8.7.1 Medicago Company Information
  39. 8.7.2 Medicago Business Overview
  40. 8.7.3 Medicago Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Medicago Virus Like Particles Product Portfolio
  42. 8.7.5 Medicago Recent Developments
  43. 8.8 MedImmune
  44. 8.8.1 MedImmune Company Information
  45. 8.8.2 MedImmune Business Overview
  46. 8.8.3 MedImmune Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 MedImmune Virus Like Particles Product Portfolio
  48. 8.8.5 MedImmune Recent Developments
  49. 8.9 Novavax
  50. 8.9.1 Novavax Company Information
  51. 8.9.2 Novavax Business Overview
  52. 8.9.3 Novavax Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novavax Virus Like Particles Product Portfolio
  54. 8.9.5 Novavax Recent Developments
  55. 8.10 Serum Institute of India
  56. 8.10.1 Serum Institute of India Company Information
  57. 8.10.2 Serum Institute of India Business Overview
  58. 8.10.3 Serum Institute of India Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Virus Like Particles Product Portfolio
  60. 8.10.5 Serum Institute of India Recent Developments
  61. 8.11 TechnoVax
  62. 8.11.1 TechnoVax Company Information
  63. 8.11.2 TechnoVax Business Overview
  64. 8.11.3 TechnoVax Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 TechnoVax Virus Like Particles Product Portfolio
  66. 8.11.5 TechnoVax Recent Developments
  67. 8.12 Xiamen Innovax Biotech
  68. 8.12.1 Xiamen Innovax Biotech Company Information
  69. 8.12.2 Xiamen Innovax Biotech Business Overview
  70. 8.12.3 Xiamen Innovax Biotech Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Xiamen Innovax Biotech Virus Like Particles Product Portfolio
  72. 8.12.5 Xiamen Innovax Biotech Recent Developments
  73. 8.13 GlaxoSmithKline
  74. 8.13.1 GlaxoSmithKline Company Information
  75. 8.13.2 GlaxoSmithKline Business Overview
  76. 8.13.3 GlaxoSmithKline Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 GlaxoSmithKline Virus Like Particles Product Portfolio
  78. 8.13.5 GlaxoSmithKline Recent Developments
  79. 8.14 Merck
  80. 8.14.1 Merck Company Information
  81. 8.14.2 Merck Business Overview
  82. 8.14.3 Merck Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Merck Virus Like Particles Product Portfolio
  84. 8.14.5 Merck Recent Developments
  85. 8.15 Takeda
  86. 8.15.1 Takeda Company Information
  87. 8.15.2 Takeda Business Overview
  88. 8.15.3 Takeda Virus Like Particles Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Takeda Virus Like Particles Product Portfolio
  90. 8.15.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Virus Like Particles Value Chain Analysis
  2. 9.1.1 Virus Like Particles Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Virus Like Particles Sales Mode & Process
  6. 9.2 Virus Like Particles Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Virus Like Particles Distributors
  9. 9.2.3 Virus Like Particles Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst